Wall Street analysts forecast that Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) will post earnings per share of ($0.05) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Ritter Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.06) and the highest estimate coming in at ($0.04). Ritter Pharmaceuticals reported earnings of ($0.74) per share during the same quarter last year, which indicates a positive year over year growth rate of 93.2%. The firm is scheduled to issue its next quarterly earnings report on Monday, February 26th.

On average, analysts expect that Ritter Pharmaceuticals will report full-year earnings of ($0.66) per share for the current financial year, with EPS estimates ranging from ($1.51) to ($0.35). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.33) per share, with EPS estimates ranging from ($0.40) to ($0.20). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Ritter Pharmaceuticals.

Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.14) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14).

Several research analysts recently weighed in on the company. Zacks Investment Research raised Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research note on Tuesday, September 26th. HC Wainwright decreased their target price on Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating for the company in a research note on Monday, October 23rd. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $2.92.

A hedge fund recently bought a new stake in Ritter Pharmaceuticals stock. Susquehanna International Group LLP purchased a new stake in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,222,522 shares of the biotechnology company’s stock, valued at approximately $778,000. Susquehanna International Group LLP owned 4.49% of Ritter Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 33.38% of the company’s stock.

Ritter Pharmaceuticals (RTTR) opened at $0.30 on Friday. Ritter Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $3.75.

COPYRIGHT VIOLATION NOTICE: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/09/ritter-pharmaceuticals-inc-rttr-expected-to-announce-earnings-of-0-05-per-share.html.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.